Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

CARL. Therapy

CARL Therapy is a new method of resuscitation following cardio-circulatory arrest (“sudden death”), which was developed in an interdisciplinary collaboration of physicians and perfusionists at the Department of Cardiovascular Surgery at Freiburg University Hospital. The innovative approach addresses the frequent occurrence of sudden death which is treatable to a very limited extent so far, even under optimal conditions.

When the heart stops beating.

The human organism depends on a continuous blood flow as blood supplies all cells, tissues and organs with essential nutrients and ensures the removal of metabolic products. If the heart stops, this circulation is interrupted (ischemia) and the energy balance of the cells and organs is impaired within seconds. Subsequently, ischemic damage triggers a series of metabolic adaptations in the cells.

Back on track.

In this situation the pre-damaged organism of an affected patient meets the efforts of first responders and later rescue personnel trying to restore circulation (reperfusion) and to provide oxygen as quickly as possible. This is part of routine cardio-pulmonary-resuscitation (CPR) which includes initially cardiac massage and lay respiratory support (mouth-to-mouth or mouth-to-nose).

Within the framework of an advanced CPR performed by medical staff, the patient is intubated, defibrillated and supplied with appropriate medication. By these means, cardiopulmonary circulation can ideally be restored, and the patient may be transferred to a hospital where the cause of the cardiac arrest can be treated.

Controlled Automated Reperfusion
of the Whole Body

High osmolarity
Limiting edema formation
High blood pressure
Improving capillary blood circulation
Integrated blood gas analysis
Early optimization of metabolic pathways
High pulsatile blood flow
Restoring sufficient perfusion
Controlled oxygenation
Preventing reoxygenation injuries
Rapid cooling
Lowering energy consumption


Race against time.

However, the chances of successful resuscitation without neurological sequelae are low as the methods established to date are limited in regard to therapeutical possibilities. Only about ten per cent of all patients survive cardiovascular arrest outside a hospital, afterwards often suffering severe long-term neurological damage. Above all, the brain reacts extremely sensitive to interrupted circulation – but according to recent findings, this refers less to the consequences of ischemia than to the consequences of an uncontrolled resumption of blood flow.

The injurious impact in the phase of reperfusion is, among other things, due to the unspecific supply of oxygen, which cannot be adequately metabolized in the cells pre-damaged by ischemia. Thus, the highly reactive oxygen (free radicals) triggers severe damage to membranes, organelles, protein complexes and other cell components. We therefore refer to the overall damage after cardiac arrest as an ‘ischemia reperfusion injury’.

CARL Cooler Oxygenator Arterial blood gas analysis Pump 1 Pump 2 (pulsatile) Pressure sensor p2 Sensor flow and bubble detection Manual dosing system Ambient air Gas supply Pressure sensor p1 Sensor venous BGA Bubble trap Pressure sensor p3 CARL MOX O 2 CARL Controller Arterial pressure measurement

Step-by-step resuscitation.

Within the framework of CARL Therapy, the above pathophysiological changes are taken into account and treated in a targeted manner. To this end, the body’s own circulatory system is first bridged with the aid of two blood pumps and a special tubing system (perfusion set), which is connected to the patient’s circulation via the groin vessels.

Then, important vital parameters – such as the oxygen content and pH value of the blood – are continuously measured and patient-individually modified so that the cells and therefore the whole organism can gradually recover from ischemia and re-establish physiological metabolic processes.

Physical reperfusion conditions, i.e., blood flow, blood pressure and body temperature, are also monitored and specifically adapted. The body core temperature is reduced to about 34 °C right at the beginning of the treatment as cooling supports the resuscitation process in the sense that at lower temperatures, metabolic processes run slower, thereby supporting the replenishment of cellular substrate deficiencies.

Controlled Automated Reperfusion of the whole body.

CARL Therapy is a smart method of resuscitation after cardiac arrest. It was developed in an interdisciplinary collaboration between physicians and perfusionists at the Clinic for Cardiovascular Surgery at Freiburg University Hospital.

The new treatment method concerns sudden “acute cardiac arrest”, which until now can only be treated to a very limited extent even under optimal conditions. The survival rate in a hospital is about 20%. And, outside a hospital, only 3 to 8% of all patients survive an acute cardiovascular arrest. In addition, the few patients who leave the hospital often suffer from pronounced and persistent brain damage.

CARL Therapy relies on controlled restoration of blood flow through reperfusion. The former Medical Director of Cardiovascular Surgery at the Medical Center – University of Freiburg and his team of researchers have discovered that it is thus possible to resuscitate a person even after a prolonged cardiac arrest without significant consequential damage.

3 – 8%
Survival Rate
> 20%
A rad wolf

Statement Prof. Dr.-Ing. Benk

“To establish CARL Therapy in clinical practice, numerous innovative approaches in the field of medical technology were required. The visionary challenge was to be able to automatically control both the physical and biochemical perfusion conditions during extracorporeal circulation, both inside and outside the hospital.

We met this challenge – and today we have reached the point where our smart system can start its journey into hospitals.”

Prof. Dr.-Ing. Christoph Benk
Managing Director, Resuscitec GmbH

A rad wolf

Statement Univ.-Prof. Dr. Dr. h. c. Beyersdorf

“After a cardiovascular arrest, the entire body is in a special state that must be understood very precisely and treated individually for each patient. Above all, the patient’s blood must be modified in such a way that the organs can gradually recover from the lack of oxygen supply. Based on the findings of our many years of clinical research, we have therefore developed a novel therapy for resuscitation, which we call CARL Therapy.”

Univ.-Prof. Dr. Dr. h. c. Friedhelm Beyersdorf
Founder and Initiator, Resuscitec GmbH
Former Medical Director of the Clinic of Cardiovascular Surgery at The Medical Center – University of Freiburg